Level D· Scientific groundwork from lab and animal studiesLaboratory StudyPubMed

[High-dose neuropeptide Y inhibits proliferation and promotes differentiation of human adipose-derived stem cells].

Wu W., Hu P., Liang F., Song X., Liu M.

Laboratory Study on Hip, published in Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2016) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi (2016)
Country
China
Reported sample size
—
Source database
PubMed
PMID
26927378
Citations
4

Abstract (original English)

Objective To investigate the impact of neuropeptide Y (NPY) at different concentrations on the proliferation and differentiation of human adipose-derived stem cells (hADSCs). Methods The hADSCs were separated and incubated with NPY at a range of concentrations 10(-6)-10(-15) mol/L. MTT assay was used to detect cell proliferation. Following the treatment of complete medium, NPY and insulin separately, cell differentiation was observed by Oil red O staining. In addition, Western blotting was performed to exam the levels of peroxisome proliferator-activated receptor-γ (PPARγ), CCAAT/enhancer binding protein alpha (C/EBPα), cell death-inducing dFF45-like effector c (Cidec) and receptor interacting protein 140 (RIP140). Results MTT assay revealed that 10(-11)-10(-15) mol/L NPY stimulated the proliferation of hADSCs, while high-dose NPY (10(-6)-10(-10) mol/L) inhibited the cell proliferation. NPY (10(-7), 10(-9), 10(-11) mol/L) induced the differentiation of hADSCs. The expression levels of related adipocyte markers (PPARγ, C/EBPα), mature white adipose tissue specific markers (Cidec, RIP140) increased at the presence of NPY (10(-7), 10(-9), 10(-11) mol/L). Conclusion Low-dose NPY could stimulate the proliferation of hADSCs, and high-dose NPY could inhibit the proliferation and promote the differentiation of hADSCs.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Adaptor Proteins, Signal TransducingAdipose TissueApoptosis Regulatory ProteinsBlotting, WesternCCAAT-Enhancer-Binding Protein-alphaCell DifferentiationCell ProliferationCells, CulturedDose-Response Relationship, DrugHumans

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research